- Home
- LSF vs MAIA Comparison
LSF vs MAIA Comparison
Compare LSF & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | MAIA |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8M | 89.7M |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | LSF | MAIA |
|---|---|---|
| Price | $2.47 | $1.52 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 34.2K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.28 | 29.53 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,295,137.00 | N/A |
| Revenue This Year | $15.87 | N/A |
| Revenue Next Year | $14.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 26.50 | N/A |
| 52 Week Low | $1.98 | $0.87 |
| 52 Week High | $7.94 | $3.19 |
Technical Indicators
Market Signals| Indicator | LSF | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 38.16 |
| Support Level | $2.41 | $1.44 |
| Resistance Level | $2.76 | $1.52 |
| Average True Range (ATR) | 0.19 | 0.13 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 34.81 | 12.86 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.